After a single subcutaneous dose of the GLP-1R agonist semgalutide (30 nmol/Kg), mice were given free access to water but no food or ethanol
SMPG = self-measured plasma glucose
G., Bratt, T
To achieve improved half-life, the inclusion of chemical modifications such as the use of D-amino acids, non-natural amino acids (e.g., ornithine), PEGylation and N and C-terminal modifications have been extensively employed
[3][6] NLEM 2022 already emphasises the growing burden of diabetes and the need for key diabetes drugs in public systems, and official documents acknowledge GLP-1 RAs as important options.[15] If liraglutide and semaglutide formulations used for diabetes are eventually brought under price control, MRPs could drop by another 2030% beyond current generic competition, especially where innovator prices remain high
Conclusion: DPP-4 inhibitors are potentially linked to biliary disorders, warranting vigilance